Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Combined With Trastuzumab and Albumin Paclitaxel in HER2-positive Breast Cancer
NCT05429294Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05429294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429294.